Skip to main content
. Author manuscript; available in PMC: 2009 Jun 24.
Published in final edited form as: Biochem Pharmacol. 2008 Sep 30;77(1):114–124. doi: 10.1016/j.bcp.2008.09.023

Fig. 3.

Fig. 3

Binding affinities and potencies of [DPhe6]-γ-MSH and [Pro5, DNaI (2′)a]-γ-MSH at hMC4R/TM2hMC1R, hMC4R/TM3hMC1R and hMC4R/TM3hMC1R. Panel A depicts the binding affinity of [DPhe6]-γ-MSH as determined by inhibition of 125INDP-MSH binding at the chimeric receptors. Panel B represents the ability of [DPhe6]-γ-MSH to stimulate the production of intracellular cAMP at the chimeric receptors. Panel G depicts the binding affinity of [Pro5, DNaI (2′)8]-γ-MSH as determined by inhibition of 125INDP-MSH binding at the chimeric receptors. Panel D represents the ability of [Pro5, DNaI (2′)8]-γ-MSH to stimulate the production of intracellular cAMP at the chimeric receptors. Data points represent the mean ± S.E.M. of at least three independent experiments.